文献速递心脑血管急症重症综合管理与镇静镇痛

急性失代偿性心力衰竭中的血管紧张素-脑啡肽酶抑制

Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
PubMed 文献 · N Engl J Med · 2018-11-11
一句话结论因急性失代偿性心力衰竭住院的射血分数降低心衰患者,血流动力学稳定后启用沙库巴曲缬沙坦较依那普利更显著降低NT-proBNP,安全终点无显著差异。

PIONEER-HF研究在美国129个中心纳入因急性失代偿性心力衰竭住院的射血分数降低心衰患者,血流动力学稳定后随机接受沙库巴曲缬沙坦(目标剂量沙库巴曲97 mg/缬沙坦103 mg每日两次)或依那普利(目标剂量10 mg每日两次)。主要疗效终点为基线至第4周和第8周NT-proBNP的时间平均比例变化,沙库巴曲缬沙坦组几何均值比值0.53 vs 依那普利组0.75(变化百分比-46.7% vs -25.3%,比值0.71,95%CI 0.63-0.81,P<0.001)。第1周即观察到更大降幅(比值0.76,95%CI 0.69-0.85)。肾功能恶化、高钾血症、症状性低血压和血管性水肿发生率两组无显著差异。

要点

  • 因急性失代偿性心衰住院的HFrEF患者,血流动力学稳定后启用沙库巴曲缬沙坦,第4周和第8周NT-proBNP几何均值比值0.53 vs 依那普利0.75,变化百分比-46.7% vs -25.3%(比值0.71,95%CI 0.63-0.81,P<0.001)。
  • NT-proBNP降幅在第1周即显现,沙库巴曲缬沙坦 vs 依那普利比值0.76(95%CI 0.69-0.85)。
  • 肾功能恶化、高钾血症、症状性低血压和血管性水肿发生率两组无显著差异。
  • 沙库巴曲缬沙坦目标剂量为沙库巴曲97 mg/缬沙坦103 mg每日两次;依那普利目标剂量10 mg每日两次。
  • 研究纳入881例患者,沙库巴曲缬沙坦组440例,依那普利组441例。

适用人群与场景

  • 因急性失代偿性心力衰竭住院的射血分数降低心衰患者,来自美国129个中心。
  • 患者经血流动力学稳定后纳入随机分组。

处置流程与药物剂量

  • 血流动力学稳定后随机给予沙库巴曲缬沙坦,目标剂量为沙库巴曲97 mg与缬沙坦103 mg每日两次。
  • 对照方案为依那普利,目标剂量10 mg每日两次。

研究设计与关键结果

  • 研究类型为随机对照试验,纳入881例因急性失代偿性心力衰竭住院的射血分数降低心衰患者,沙库巴曲缬沙坦组440例、依那普利组441例。
  • 主要疗效终点为基线至第4周和第8周NT-proBNP的时间平均比例变化,沙库巴曲缬沙坦组几何均值比值0.53 vs 依那普利组0.75,变化百分比-46.7% vs -25.3%,比值0.71(95%CI 0.63-0.81,P<0.001)。
  • 第1周NT-proBNP变化比值沙库巴曲缬沙坦 vs 依那普利为0.76(95%CI 0.69-0.85)。
  • 肾功能恶化、高钾血症、症状性低血压和血管性水肿发生率两组无显著差异。

证据类型、等级与局限

  • 随机对照试验(PIONEER-HF,NCT02554890),由诺华资助。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 对因急性失代偿性心力衰竭住院的射血分数降低心衰患者,在血流动力学稳定后启用沙库巴曲缬沙坦较依那普利更大幅度降低NT-proBNP,且所报告的安全终点无显著差异。
  • 原文未据此给出推荐

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of sacubitril-valsartan therapy is safe and effective among patients who are hospitalized for acute decompensated heart failure is unknown.

METHODS: We enrolled patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure at 129 sites in the United States. After hemodynamic stabilization, patients were randomly assigned to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or enalapril (target dose, 10 mg twice daily). The primary efficacy outcome was the time-averaged proportional change in the N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration from baseline through weeks 4 and 8. Key safety outcomes were the rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema.

RESULTS: Of the 881 patients who underwent randomization, 440 were assigned to receive sacubitril-valsartan and 441 to receive enalapril. The time-averaged reduction in the NT-proBNP concentration was significantly greater in the sacubitril-valsartan group than in the enalapril group; the ratio of the geometric mean of values obtained at weeks 4 and 8 to the baseline value was 0.53 in the sacubitril-valsartan group as compared with 0.75 in the enalapril group (percent change, -46.7% vs. -25.3%; ratio of change with sacubitril-valsartan vs. enalapril, 0.71; 95% confidence interval [CI], 0.63 to 0.81; P<0.001). The greater reduction in the NT-proBNP concentration with sacubitril-valsartan than with enalapril was evident as early as week 1 (ratio of change, 0.76; 95% CI, 0.69 to 0.85). The rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema did not differ significantly between the two groups.

CONCLUSIONS: Among patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure, the initiation of sacubitril-valsartan therapy led to a greater reduction in the NT-proBNP concentration than enalapril therapy. Rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema did not differ significantly between the two groups. (Funded by Novartis; PIONEER-HF ClinicalTrials.gov number, NCT02554890 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2018. PMID: 30415601. doi:10.1056/NEJMoa1812851

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。